Sung, H. et al. World Cancer Statistics 2020: GLOBOCAN estimates of worldwide incidence and mortality for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
Qiu, H., Cao, S. & Xu, R. Cancer incidence, mortality and burden in China: a temporal trend analysis and comparison with the United States and the United Kingdom based on published global epidemiological data in 2020. Common Cancer. (London.) 41(10), 1037-1048 (2021).
Cao, M., Li, H., Sun, D. & Chen, W. Cancer burden of major cancers in China: A need for sustainable actions. Common Cancer. (London.) 40(5), 205–210 (2020).
Zeng, H. et al. Change in cancer survival in China between 2003 and 2015: a pooled analysis of 17 population-based cancer registries. Lancet Glob. Health 6(5), e555–e567 (2018).
Practice Bulletin Number 179. Breast cancer risk assessment and screening in women at average risk. Obstet. Gynecol. 130(1), e1–e16 (2017).
Lilyquist, J., Ruddy, KJ, Vachon, CM & Couch, FJ Common genetic variation and past, present, and future breast cancer risk. Cancer epidemiology. Biomark. Prev. 27(4), 380–394 (2018).
Fanale, D. et al. Genome-wide association studies of breast cancer: There is strength in numbers. Oncogene 31(17), 2121-2128 (2012).
Carmeliet, P. & Jain, RK Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298–307 (2011).
Saharinen, P., Eklund, L. & Alitalo, K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat. Rev. Drug Discov. 16(9), 635–661 (2017).
Konac, E. et al. Absence of association between −460 C/T and 936 C/T of vascular endothelial growth factor and polymorphisms of angiopoietin-2 exon 4 G/A and cancers of the ovary, cervix uterus and endometrium. Cell DNA Biol. 26(7), 453–463 (2007).
Bhatraju, Pennsylvania et al. Genetic variation implicates plasma angiopoietin-2 in the development of acute kidney injury subphenotypes. BMC Nephrol. 21(1), 284 (2020).
Dai, C. et al. Correlation between the genetic polymorphism of the angiopoietin-2 gene and the clinical aspects of rheumatoid arthritis. Int. J.Med. Science. 16(2), 331–336 (2019).
Hou, W. et al. Correlations between angiopoietin-2 gene polymorphisms and lung cancer progression in a Chinese Han population. J.Cancer ten(13), 2935-2941 (2019).
World Medical, A. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 310(20), 2191-2194 (2013).
Elston, CW & Ellis, IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5), 403–10 (1991).
Elston, CW & Ellis, IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41(3A), 154–61 (2002).
Wang, QC et al. Impacts of RETN genetic polymorphism on the development of breast cancer. J.Cancer 11(10), 2769–2777 (2020).
Wang, QC et al. Fascin-1 as a new diagnostic marker for triple-negative breast cancer. CancerMed. 5(8), 1983-1988 (2016).
Wang, QC et al. FSCN1 gene polymorphisms: biomarkers of breast cancer development and progression. Science. representing seven(1), 15887 (2017).
Du, Z. et al. Angiopoietin-2 gene polymorphisms are biomarkers of colorectal cancer development and progression in Han Chinese. Int. J.Med. Science. 17(1), 97–102 (2020).
Zhang, L., Zhang, Y., Tang, CH & Su, CM RAD52 gene polymorphisms are associated with colorectal cancer risk in a Chinese Han population. Medicine (Baltimore) 96(49), e8994 (2017).
Yang, YC et al. Melatonin reduces lung cancer strain by inhibiting PLC, ERK, p38, beta-catenin and Twist pathways. About. Toxicol. 34(2), 203–209 (2019).
Chen, Y.A. et al. Simvastatin sensitizes radioresistant prostate cancer cells by impairing the repair of DNA double-strand breaks. Front. Pharmacol. 9600 (2018).
King, MC, Marks, JH, Mandell, JB, New York Breast Cancer Study, G. Risks of breast and ovarian cancer due to inherited BRCA1 and BRCA2 mutations. Science 302(5645), 643–6 (2003).
Stratton, MR & Rahman, N. The emerging landscape of breast cancer susceptibility. Nat. Broom. 40(1), 17-22 (2008).
Fanfani, V., Zatopkova, M., Harris, AL, Pezzella, F. & Stracquadanio, G. Dissection of hereditary breast cancer risk: from statistical methods to susceptibility genes. Semin. Cancer Biol. 72175–184 (2021).
Yu, K., Lee, CH, Tan, PH, and Tan, P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression in distinct ethnic populations. Clin. Cancer Res. ten(16), 5508–5517 (2004).
Fan, L. et al. Breast cancer in China. Lancet Oncol. 15(7), e279–e289 (2014).
Makhoul, I. et al. Germline genetic variants of TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA are associated with pathological complete response to bevacizumab in breast cancer patients. PLoS One 12(1), e0168550 (2017).
Robinson, M. et al. Olaparib for metastatic breast cancer in patients with germline BRCA mutation. N.Engl. J.Med. 377(6), 523-533 (2017).
Chai, Y. et al. Homologous recombination deficiency (HRD) and BRCA 1/2 gene mutation to predict the effect of neoadjuvant platinum-based chemotherapy in early-stage triple-negative breast cancer (TNBC): a systematic review and meta-analysis . J.Pers. Med. 12(2), 323 (2022).
Blanco-Gomez, A. et al. Stromal SNAI2 Is required for breast cancer progression ERBB2. Cancer Res. 80(23), 5216–5230 (2020).
Devlin, B. & Risch, N. A comparison of linkage disequilibrium metrics for fine-scale mapping. Genomics 29(2), 311–322 (1995).
Shifman, S. et al. A highly significant association between a COMT haplotype and schizophrenia. A m. J. Hum. Broom. 71(6), 1296–1302 (2002).